Abstract 146P
Background
The CROSS and NEOCRTEC-5010 trials established neoadjuvant chemoradiotherapy (nCRT) as the standard for locally advanced esophageal cancer (EC). The ESCORT-NEO study showed the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, reports on the combined approach in adenocarcinoma of the esophagogastric junction (AEG) are lacking. This phase II trial evaluates the efficacy and safety of neoadjuvant adebrelimab with nab-paclitaxel, lobaplatin, and S-1 in resectable locally advanced AEG.
Methods
Treatment-naive patients with cT3-4NanyM0 resectable locally advanced AEG and ECOG PS 0-1 received adebrelimab (1200 mg IV) on Day 1, nab-paclitaxel (180-200 mg IV) on Day 1, lobaplatin (50 mg IV 2h) on Day 1, and S-1 (40 mg, bid po) every 3 weeks for 2 cycles, followed by surgery and investigator's choice of adjuvant treatment. The primary endpoint was the pathologic complete response (pCR) rate; secondary endpoints included R0 resection rate, overall response rate (ORR), event-free survival (EFS), disease-free survival (DFS), safety.
Results
From November 2023 to June 2024, 15 patients were enrolled and completed neoadjuvant treatment; 2 patients were lost to follow-up, and 5 refused surgery. Among the 8 patients who underwent surgery, 1 (12.5%) achieved pCR, and all achieved R0 resection. Tumor regression grades (TRG) observed were TRG0 in 1 (12.5%), TRG2 in 5 (62.5%), and TRG3 in 2 (25.0%) patients. Of the 13 evaluable patients, 8 (62%) achieved partial response (PR) and 5 (38%) had stable disease (SD). ORR and DCR were 62% (8/13) and 100.0% (13/13), respectively. Treatment-related adverse events (TRAEs) occurred in 100% of patients, but no grade 3-5 TRAEs were observed. Toxicity and post-surgery complications were limited, and surgical feasibility was not impacted.
Conclusions
Neoadjuvant adebrelimab combined with chemotherapy, followed by surgery and adjuvant treatment, demonstrated good efficacy and safety in patients with resectable locally advanced AEG, offering a promising treatment option for this patient population.
Clinical trial identification
NCT06198465.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
Resources:
Abstract